HTG Molecular Diagnostics Inc (HTGM)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: LABORATORY ANALYTICAL INSTRUMENTS

3430 E. GLOBAL LOOP TUCSON, AZ 85706

HTG Molecular Diagnostics Inc. is focused on NGS-based molecular profiling. The Company's proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG's customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Its mission is to empower precision medicine.

Data as of 2021-09-11 11:32:46 -0400
Market Cap43.511 Million Shares Outstanding7.413 Million Avg 30-day Volume60.691 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS0
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE-1.88 Enterprise Value
Total Cash Current Debt Gross Profit
BETA0.27035 52-week High/Low7.95 / 3.5 Next Earnings Date2021-11-09 Price to Cash FLow (P/CF) -7.4546
Data provided by IEX Cloud
View SEC Filings from HTGM instead.

View recent insider trading info

Funds Holding HTGM (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding HTGM BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

LAFRANCE JAMES T

  • Director
4,000 2021-08-18 1

HARDISON DON M

  • Director
4,000 2021-08-18 1

GRIFFIN MICHELLE RENEE

  • Director
4,000 2021-08-18 1

HANHAM ANN

  • Director
4,000 2021-08-18 1

MCCRACKEN LEE R.

  • Director
4,000 2021-08-18 1

GEORGE HARRY A.

  • Director
4,000 2021-08-18 1

MCMEANS SHAUN D SVP, FINANCE & ADMIN. & CFO

  • Officer
8,172 2021-06-30 6

LUBNIEWSKI JOHN L PRESIDENT & CEO

  • Officer
  • Director
11,380 2021-06-30 6

LAWSON BYRON SVP/CHIEF COMMERCIAL OFFICER

  • Officer
3,231 2021-06-30 6

GODLEWSKI LAURA LEE VP FINANCE, PRIN ACCT OFFR

  • Officer
1,904 2021-06-10 2

JOHNSON TIM B EXECUTIVE CHAIRMAN

  • Officer
  • Director
16,738 2020-12-31 3

LYTTON LAURENCE W

  • 10% Owner
No longer subject to file 2020-02-25 0

ROCHE PATRICK C. SVP MEDICAL/SCIENTIFIC AFFAIRS

  • Officer
43,421 2018-06-08 0

GORDON DEBRA A SVP, CHIEF LEGAL COUNSEL

  • Officer
72,552 2018-01-29 0

QIAGEN NV

  • 10% Owner
0 2017-10-26 0

NOVO HOLDINGS A/S

  • 10% Owner
No longer subject to file 2017-08-23 0

SHUSTER LEWIS

  • Director
0 2017-08-15 0

GLAXOSMITHKLINE PLC

  • FORMER 10% OWNER
No longer subject to file 2017-03-27 0

GRIMM DONALD W

  • Director
0 2015-05-11 0

FLETCHER SPAGHT VENTURES II LP

FSV II LP

FSV II-B LP

  • 10% Owner
No longer subject to file 2015-05-11 0

MERCK CAPITAL VENTURES LLC

SENOUR LAWRENCE D.

  • 10% Owner
No longer subject to file 2015-05-11 0

GEORGE SIMEON

  • Director
0 2015-05-05 0

BISGAARD PETER

  • Director
0 2015-05-05 0

HOULT MARY

  • Director
0 2015-05-05 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

GEORGE HARRY A. - Director

2021-08-19 17:12:27 -0400 2021-08-18 A 4,000 a 4,000 direct

GRIFFIN MICHELLE RENEE - Director

2021-08-19 17:21:27 -0400 2021-08-18 A 4,000 a 4,000 direct

HANHAM ANN - Director

2021-08-19 17:14:33 -0400 2021-08-18 A 4,000 a 4,000 direct

LAFRANCE JAMES T - Director

2021-08-19 17:17:17 -0400 2021-08-18 A 4,000 a 4,000 direct

HARDISON DON M - Director

2021-08-19 17:15:54 -0400 2021-08-18 A 4,000 a 4,000 direct

MCCRACKEN LEE R. - Director

2021-08-19 17:18:45 -0400 2021-08-18 A 4,000 a 4,000 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
HTG MOLECULAR DIAGNOSTICS HTGM 2021-09-16 22:15:03 UTC -3.2415 3.3115 150000
HTG MOLECULAR DIAGNOSTICS HTGM 2021-09-16 21:45:03 UTC -3.2415 3.3115 150000
HTG MOLECULAR DIAGNOSTICS HTGM 2021-09-16 21:15:03 UTC -3.2415 3.3115 150000
HTG MOLECULAR DIAGNOSTICS HTGM 2021-09-16 20:45:02 UTC -3.2415 3.3115 150000
HTG MOLECULAR DIAGNOSTICS HTGM 2021-09-16 20:15:03 UTC -3.2415 3.3115 150000
HTG MOLECULAR DIAGNOSTICS HTGM 2021-09-16 19:45:03 UTC -3.2415 3.3115 150000
HTG MOLECULAR DIAGNOSTICS HTGM 2021-09-16 19:15:02 UTC -3.2415 3.3115 150000
HTG MOLECULAR DIAGNOSTICS HTGM 2021-09-16 18:45:03 UTC -3.2415 3.3115 150000
HTG MOLECULAR DIAGNOSTICS HTGM 2021-09-16 18:15:03 UTC -3.2415 3.3115 150000
HTG MOLECULAR DIAGNOSTICS HTGM 2021-09-16 17:45:03 UTC -3.2415 3.3115 150000
HTG MOLECULAR DIAGNOSTICS HTGM 2021-09-16 17:15:03 UTC -3.2415 3.3115 150000
HTG MOLECULAR DIAGNOSTICS HTGM 2021-09-16 16:45:03 UTC -3.2415 3.3115 150000
HTG MOLECULAR DIAGNOSTICS HTGM 2021-09-16 16:15:04 UTC -3.2415 3.3115 150000
HTG MOLECULAR DIAGNOSTICS HTGM 2021-09-16 15:45:03 UTC -3.2415 3.3115 150000
HTG MOLECULAR DIAGNOSTICS HTGM 2021-09-16 15:15:03 UTC -3.2415 3.3115 150000
HTG MOLECULAR DIAGNOSTICS HTGM 2021-09-16 14:45:03 UTC -3.3902 3.4602 150000
HTG MOLECULAR DIAGNOSTICS HTGM 2021-09-16 14:15:03 UTC -3.3902 3.4602 150000
HTG MOLECULAR DIAGNOSTICS HTGM 2021-09-16 13:45:03 UTC -3.3902 3.4602 150000
HTG MOLECULAR DIAGNOSTICS HTGM 2021-09-16 13:15:03 UTC -3.3902 3.4602 150000
HTG MOLECULAR DIAGNOSTICS HTGM 2021-09-16 12:45:03 UTC -3.3902 3.4602 150000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund HTGM -833.0 shares, $-4839.73 2021-06-30 N-PORT

Elevate your investments